Robert L. Bratzler

Sumitomo Pharma America, Inc. operates as a biopharmaceutical company that develops pharmaceutical products. Its products include Aptiom (eslicarbazepine acetate) tablets, Latuda (lurasidone HCl) tablets, Lunesta (eszopiclone) tablets, Xopenex (levalbuterol HCl) Inhalation Solution, Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, Brovana (arformoterol tartrate) Inhalation Solution, Omnaris (ciclesonide) Nasal Spray, Alvesco (ciclesonide) Inhalation Aerosol, and Zetonna (ciclesonide) Nasal Aerosol. The company was founded in 2010 and is headquartered in Marlborough, MA.

Coley Pharmaceutical Group, Inc. manufactures drugs to treat chronic diseases. The company discovers and develops receptors therapeutic candidates for cancers, asthma, and allergic disorders. It was founded in 1997 and is headquartered in Wellesley, MA

Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its portfolio includes pipeline, autoimmune, gene therapy, and biologic therapy. The company was founded by Omid C. Farokhzad, Robert S. Langer Jr., and Ulrich von Andrian on December 10, 2007 and is headquartered in Watertown, MA.

Senova Systems, Inc. develops and sells technology for measuring pH meters. It provides platform for the life science, food and beverage, dairy, petrochemical, water, and environmental sectors. The firm offers a pHit sensor platform which utilizes a carbon substrate containing proprietary analyte sensing molecules or ASMs. The company was founded by Gil M. Labrucherie, Robert L. Bratzler, Egisto Boschetti, Lee Leonard and Bernard Lemaitre in 2007 and is headquartered in Sunnyvale, CA.

Encore Pharmaceuticals, Inc. (EPI) is a drug discovery and development company with advanced proprietary products for the treatment and prevention of cancer and neurologic and cardiovascular diseases. EPI's principal drug innovations have come from discoveries made by researchers at Loma Linda University Medical Center (LLUMC). EPI was founded in 1997 and concluded a technology transfer license agreement with LLUMC in January 1999. The discovery operation continues to be located in the LLUMC environment where operations in 1999 were expanded to include clinical development of EPI's lead drug candidate E-7869 (now known as MPC-7869) for treatment of prostate and colon cancer. The company's research efforts have also led to the discovery of a -tocopherol (member of the Vitamin E family) metabolite designated as E-8110 (also known as LLU- ) and bioanalogs which have natriuretic (sodium excretion) activity. These compounds are being examined for their anti-hypertensive, anti-oxidant and anti-cancer properties. Patent applications for EPI drug discoveries have been filed and are in review worldwide

Xiphos Pharmaceuticals, Inc. provides pharmaceuticals and medical products and services. The company was founded by Grayson B. Lipford and is headquartered in Concord, MA